MedTrace Logo

Trial in Adult Subjects With Acute Migraines

NCT03461757 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1811

Last updated 2023-02-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.

Conditions

  • Migraine, With or Without Aura

Interventions

DRUG

Rimegepant

75 mg ODT QD

DRUG

Placebo

Placebo ODT to match rimegepant dose QD

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2018-10-08
Completion
2018-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03461757 on ClinicalTrials.gov